Thomas Williams, a company director at Sherwin-Williams (SHW), received deferred equity under the 2005 Director Deferred Fee Plan on 10/03/2025. The filing reports 1,813 deferred stock units and common shares credited to his account, calculated using a weighted average share price of $343.81 to determine unit amounts. The deferred stock units are payable only in stock, generally after the director leaves service, and include units credited via a dividend reinvestment feature. The filing also notes ownership following the transaction of 953.23 (reported as beneficially owned) under an indirect form, and that 1,147 RSUs plus 666 shares comprise the 1,813 figure.
Sherwin-Williams Co. (SHW) director Michael H. Thaman reported changes in his beneficial ownership on 10/03/2025 in a Form 4 filing. The filing shows an acquisition of deferred stock units under the 2005 Director Deferred Fee Plan and a disposition of 7,553 common stock-related holdings. The filing states 98.17 deferred stock units were credited using a weighted average share price of $343.81, and it lists 5,370.62 as the amount of securities beneficially owned following the transaction (identified as indirect ownership). The disposition entry lists 7,553 which the filing explains consists of 1,150 restricted stock units and 6,403 shares of common stock. The deferred units are payable solely in stock and generally become payable after the reporting person separates from service as a director.
Robert J. Gamgort, a director of Sherwin-Williams Co. (SHW), reported changes in his beneficial ownership on 10/03/2025. He acquired 98.17 deferred stock units under the 2005 Director Deferred Fee Plan at a weighted average price of $343.81, and disposed of 517 restricted stock units (RSUs). After the reported transactions he beneficially owns 281.71 deferred stock units held indirectly; the deferred units are payable in shares following separation from service.
Kerrii B. Anderson, a director of Sherwin-Williams (SHW), reported changes in beneficial ownership on 10/03/2025. The filing shows the director acquired deferred stock units under the 2005 Director Deferred Fee Plan equal to 29.09 units at a weighted average price of $343.81 per share; those deferred units are payable in stock, generally after separation from service. The report also shows a disposition of 5,261 common stock-related instruments, comprised of 1,150 restricted stock units (RSUs) and 4,111 shares of common stock. Following the transaction, the reporting person beneficially owned 979.69 deferred stock units indirectly.
Sherwin-Williams completed a strategic acquisition and secured short-term financing to fund it. The company and its Luxembourg unit entered a 364-day senior unsecured delayed draw term loan agreement providing a $750 million USD tranche and a e2 82 ac250 million EUR tranche, and on September 25, 2025 both tranches were drawn to fund part of a previously announced transaction. On October 1, 2025 a wholly owned Brazilian subsidiary closed the purchase of Suvinil Coatings S.A., BASFs Brazilian architectural paints business, for $1.15 billion, subject to customary working capital and post-closing adjustments.
Reporting person: Justin T. Binns, President, Global Architectural at The Sherwin-Williams Company (SHW). On 08/25/2025 Mr. Binns exercised employee stock options and completed offsetting market activity that netted a modest change in holdings. He exercised options with a $79.85 exercise price covering 609 shares and recorded an acquisition of 609 common shares at $79.85. The same day he sold 609 common shares at $368.82. After these transactions he beneficially owned 17,922 shares directly and had 5,891.02 shares attributable indirectly via the company 401(k) plan per the trustee statement dated 06/30/2025. The filing lists 4,175 restricted stock units included in the reported totals and notes the relevant options were granted in 2015 and vested over three years.
The filing is a Form 144 notice for The Sherwin-Williams Company (SHW) reporting a proposed sale of 609 common shares with an aggregate market value of $224,612.29. The shares represent a very small fraction of the company's 249,333,316 shares outstanding. The proposed sale date is 08/25/2025 on the NYSE. The shares were acquired pursuant to an option granted on 10/16/2015 and are recorded as acquired on 08/25/2025, with payment in cash. The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information.
The Sherwin-Williams Company entered into material credit arrangements on August 8, 2025 to extend its revolving credit and add a near‑term delayed draw term loan facility to support corporate liquidity. The company and certain subsidiaries amended the existing revolving credit agreement to extend the maturity from July 31, 2029 to August 8, 2030, removed a credit spread adjustment tied to Term SOFR and revised the pricing grid.
Separately, Sherwin‑Williams and a Luxembourg subsidiary agreed a 364‑day delayed draw term loan facility comprising a $750 million USD tranche and a €250 million Euro tranche, available in a single draw through October 31, 2025 and maturing 364 days from funding. The company guarantees the Euro tranche and the DDTL includes a consolidated leverage covenant capped at 3.75:1 (temporarily 4.25:1 after a qualifying acquisition for four quarters).
On 08/06/2025, James P. Lang, Senior Vice-President – Enterprise Finance & Chief Accounting Officer of The Sherwin-Williams Company (SHW), filed a Form 4 detailing an option exercise and share sale.
• Lang exercised 860 employee stock options (grant 10/16/2019) at an exercise price of $186.85 (code “M”).
• He immediately sold the 860 acquired shares at a market price of $350.35 (code “S”), generating gross proceeds of roughly $301 k.
Post-transaction holdings:
- 377 SHW common shares held directly (down from 1,237 before the sale).
- 1,016.34 shares held indirectly via the company 401(k) plan.
- Zero derivative securities remain outstanding.